 |
| REFERENCIAS |
|
- Wingard JR, Leather HL. Empiric antifungal therapy for the neutropenic patient. Oncology. 2001;15(3):351–364.
- Datos en archivo MSD.
- Vazquez JA, Lynch M, Boikov D, y cols. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and resistant Candida species. Antimicrob Agents Chemother. 1997;41(7):1612–1614.
- Pfaller Ma, Marco F, Messer SA, y cols. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,872) against clinical isolates of aspergillus, fusarium, rhizopus and other filamentous fungi. Diagn Microbiol Infect Dis. 1998;30:251–255.
- Abruzzo GK, Flattery AM, Gill CJ, y cols. Evaluation of the echinocandin antifungal MK-0991 (L743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother. 1997;41(11):2333–2338.
- Ernst EJ, Klepser ME, Pfaller Ma. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Crytococcus neoformans. Antimicrob Agents Chemother. 2000:44:1108–1111.
- Douglas CM. Understanding the microbiology of the Aspergillus cell wall and the efficacy of caspofungin. Med Mycol. 2006:44:595–599.
- Pfaller Ma, Boyken L, Hollis RJ, y cols. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microb. 2006;44(3):760–763.
- Kartsonis N, Killar J, Mixson L, y cols. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agent Chemother. 2005;49(9):3616–3623.
|
|
|
|
|
|
|
|
